Results 91 to 100 of about 2,713,900 (282)

Design Space Identification and Visualization for Continuous Pharmaceutical Manufacturing

Pharmaceutics, 2020
Progress in continuous flow chemistry over the past two decades has facilitated significant developments in the flow synthesis of a wide variety of Active Pharmaceutical Ingredients (APIs), the foundation of Continuous Pharmaceutical Manufacturing (CPM),
Samir Diab, Dimitrios I. Gerogiorgis
semanticscholar   +1 more source

Continuous direct compression as manufacturing platform for sustained release tablets [PDF]

, 2017
This study presents a framework for process and product development on a continuous direct compression manufacturing platform. A challenging sustained release formulation with high content of a poorly flowing low density drug was selected.
Cunningham, C., De Beer, Thomas, Holman, J., Kumar, Ashish, Remon, Jean Paul, Van Snick, Bernd, Vercruysse, Jurgen, Vervaet, Chris   +7 more
core   +1 more source

Pharmacological inhibition of the PERK pathway modulates hepatocellular carcinoma growth and immune signaling

FEBS Open Bio, EarlyView.
Pharmacological inhibition of PERK in a DEN‐induced mouse model of liver cancer does not reduce tumor burden but alters cellular stress signaling. Despite blocking PERK activity, downstream stress responses, including CHOP expression, remain active, suggesting compensatory mechanisms within the unfolded protein response that may influence tumor ...
Ada Lerma‐Clavero, Maria Kopsida, Nathalie Arendt, Hans Lennernäs, Markus Sjöblom, Femke Heindryckx   +5 more
wiley   +1 more source

Article X: Specific Measures to Achieve Implementation [PDF]

, 1998
Ye
Pearson, Graham S.
core  

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin, Liu Dong, Ying Wang, Dingxian He, Chong Yan, Jianying Xi, Haoqin Jiang, Yu Shi, Ming Guan, Chongbo Zhao, Jie Song, Sushan Luo   +11 more
wiley   +1 more source

Patient acceptability, safety and access : A balancing act for selecting age-appropriate oral dosage forms for paediatric and geriatric populations [PDF]

, 2018
© 2017 Elsevier B.V. All rights reserved.The selection and design of age-appropriate formulations intended for use in paediatric and geriatric patients are dependent on multiple factors affecting patient acceptability, safety and access.
Ernest, Terry B., Liu, Fang, Ranmal, Sejal R., Walsh, Jennifer   +3 more
core   +2 more sources

Characterization of Clinical Phenotype to Glial Fibrillary Acidic Protein Concentrations in Alexander Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To determine the concentration of glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and plasma in Alexander disease (AxD) and whether GFAP levels are predictive of disease phenotypes. Methods CSF and plasma were collected (longitudinally when available) from AxD participants and non‐AxD controls.
Amy T. Waldman, Asako Takanohashi, Joshua Y. Joung, Geraldine W. Liu, Kaley Arnold, Amy Pizzino, Walter Faig, Sarah Woidill, Sona Narula, Adeline L. Vanderver   +9 more
wiley   +1 more source

Predictive Maintenance in Pharma Manufacturing: Challenges and Strategic Directions

Engineering Proceedings
Predictive maintenance (PdM) has emerged as a critical enabler for improving reliability, operational efficiency, and regulatory compliance in pharmaceutical manufacturing.
Oumaima Manchadi, Fatima-Ezzahraa Ben-Bouazza, Aymane Edder, Idriss Tafala, Bassma Jioudi   +4 more
doaj   +1 more source

Why We Need Continuous Pharmaceutical Manufacturing and How to Make it Happen: A Summary of Thoughts from the International Symposium on Continuous Manufacturing.

Journal of Pharmacy and Science, 2019
We make the case for why continuous pharmaceutical manufacturing is essential, what the barriers are, and how to overcome them. To overcome them, government action is needed in terms of tax incentives or regulatory incentives that affect time.
C. Badman, Charles L. Cooney, R. T. Haslam, A. Florence, K. Konstantinov, M. Krumme, Salvatore Mascia, M. Nasr, B. Trout, R. Baddour   +9 more
semanticscholar   +1 more source

The Irish Pharmaceutical Industry over the Boom Period and Beyond [PDF]

The pharmaceutical industry has been one of the strongest performing sectors of the Celtic Tiger era. During the past two decades, employment growth in the sector has been strong and continuous, even when, in recent years, employment in other ...
Chris van Egeraat and Frank Barry
core